Indicateurs
1 Consultations de la notice
- Titre
- Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study
- Créateurs - sans rôle
- Michael Wechsler - National Jewish Health, Denver, CO, USAParameswaran Nair - McMaster University, and St Joseph's Healthcare Hamilton, Hamilton, CanadaBenjamin Terrier - Hospital Cochin and Universite Paris Cité, FranceBastian Walz - Medius Kliniken, University of Tübingen, Kirchheim-Teck, GermanyArnaud Bourdin - InsermDavid Jayne - Vasculitis and Lupus Service, Addenbrooke's Hospital, Cambridge, UKDavid Jackson - Guy's Severe Asthma Centre, School of Immunology & Microbial Sciences, King's College London, LondonFlorence Roufosse - Université Libre de BruxellesLena Börjesson Sjö - Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, SwedenYing Fan - Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USAMaria Jison - Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USAChristopher McCrae - Early Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USASofia Necander - Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, SwedenAnat Shavit - BioPharmaceutials Medical, AstraZeneca, Cambridge, UKClaire Walton - Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UKPeter Merkel - University of Pennsylvania
- Détails de publication
- Journal of allergy and clinical immunology, Vol.153(2), pp.AB364-AB364
- Éditeur
- Elsevier Inc
- Identifiants
- 99158853009311
- Unité académique
- Physiologie et Médecine Expérimentale du coeur et des muscles - PhyMedExp
- Langue
- English
- Type de ressource
- Journal article